Measuring how common high-risk oral HPV is in adults over 40 and testing a screening method for oropharyngeal cancer in the Czech Republic.

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The study recruits adults 40 and older into two cohorts: healthy volunteers through dental and outpatient clinics and people invited by mailed self-collection gargle kits from databases. Participants provide a gargle sample for HPV DNA testing, complete a questionnaire, and those with oral high-risk HPV will have periodic blood samples to check for circulating HPV DNA and be offered urogenital self-sampling. The project will measure oral (and, if applicable, genital) hrHPV prevalence, participation and return rates for mailed kits, and refine screening and laboratory procedures. The aim is to establish an effective, feasible methodology for oropharyngeal carcinoma screening and optimize associated testing procedures.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants aged 40 years or older at the time of enrollment.
* Individuals who are capable of rinsing the oral cavity by gargling independently.
* Signed informed consent for study participation, molecular-genetic testing, and personal data processing.

Exclusion Criteria:

\- Previously diagnosed head and neck cancer.

Where it's running

• Stomatologická klinika, Fakultní nemocnice u sv. Anny
  Brno, Czechia Recruiting
• Stomatologické centrum ARTDENT s.r.o.
  Jihlava, Czechia Recruiting
• Klinika zubního lékařství Fakultní nemocnice Olomouc
  Olomouc, Czechia Recruiting
• CLINIQ Dejvice
  Prague, Czechia Recruiting
• Masaryk Memorial Cancer Institute
  Brno, Czechia Not yet recruiting

Study contacts

• Study coordinator: Vladimira Koudelakova, Ph.D.
• Email: vladimira.koudelakova@upol.cz
• Phone: +420585632089

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sacituzumab govitecan plus cetuximab for recurrent or metastatic head and neck squamous cell cancer

  This trial will test whether combining sacituzumab govitecan with cetuximab works and is safe for people whose head and neck squamous cell cancer has returned or spread after prior immunotherapy.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07063212

• Methotrexate with erlotinib and celecoxib for recurrent or metastatic head and neck cancer in rural Midwest patients

  This trial tests whether combining methotrexate, erlotinib, and celecoxib can help adults in the rural Midwest whose head and neck cancer has returned or spread.

  Recruiting Phase 2 Mayo Clinic · Rochester, Minnesota · NCT06997068

• Treatment for head and neck cancer using tailored radiotherapy and ATRA

  This study is testing if a new combination of a cancer drug called ATRA with personalized radiotherapy can help people with certain types of head and neck cancer live longer and feel better.

  Recruiting at 8 sites Phase 3 Centre Leon Berard · Lyon, France and 7 other locations · NCT06706401

• Exploring the links between cancer, undernutrition, and sensory changes

  This study looks at how newly diagnosed cancers in the mouth, throat, colon, and liver affect patients' nutrition and senses like taste and smell, to see how these changes impact their eating habits and quality of life.

  Recruiting Centre Hospitalier Universitaire Dijon · Dijon · NCT06600295

• Reducing radiation volume in oropharyngeal cancer treatment

  This study is testing a personalized way to reduce radiation for people with oropharyngeal cancer to see if it can lower side effects while still being effective.

  Recruiting at 7 sites Phase 2 University of Zurich · Zurich, Canton of Zurich and 6 other locations · NCT06563362

• Lowering radiation doses for low-risk HPV oropharyngeal cancer patients

  This study is testing if giving a lower dose of radiation to patients with low-risk HPV oropharyngeal cancer after surgery can still be effective while reducing side effects.

  Recruiting Georgetown University · Washington D.C., District of Columbia · NCT06554158

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.